Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s

Novo Nordisk gets global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisk’s Wegovy. The post Novo Nordisk Lands Lexicon Pharma Obesity…

Read More

Meeting Patients Where They Are: The Value of Innovation & Collaboration in Expanding Kidney Care Access

This requires leveraging technology and partnerships in new ways to break down traditional barriers, designing therapies to fit more seamlessly into patients’ lives, and creating more equitable access to life-sustaining treatments. The post Meeting Patients Where They Are: The Value of Innovation & Collaboration in Expanding Kidney Care Access appeared first on MedCity News.

Read More

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

That is the title of a new paper out last week in Future Oncology with co-authors Kejal Jadhav, Cheryl Warren, Sabiha Quddus, Nadine Zawadzki, Daisy Yang, Andrea Damon, Kathryn Spurrier, Katharine Batt and David Wei. The abstract is below. ObjectiveTyrosine kinase inhibitors (TKIs) have transformed the prognosis of chronic myeloid leukemia (CML) into a manageable…

Read More

Only 2 weeks left for January 1 coverage

Apply for, renew, or change your Marketplace plan by December 15 to make sure your coverage starts January 1.   Image Already have Marketplace coverage? Whether you want to keep your current coverage or you’re ready for a change, you should log into your account to update any income or household changes for next year. This…

Read More